Spots Global Cancer Trial Database for cilengitide
Every month we try and update this database with for cilengitide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma | NCT00006222 | Sarcoma | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide Imaging Trial in Glioblastoma | NCT01558687 | Supratentorial ... | Drug (including... Standard therap... | 18 Years - 70 Years | Merck KGaA, Darmstadt, Germany | |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | NCT00082875 | Stage III Melan... Stage IV Melano... | cilengitide pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| EMD 121974 in Treating Patients With Progressive or Recurrent Glioma | NCT00006093 | Brain and Centr... | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status | NCT00689221 | Glioblastoma | Cilengitide Temozolomide Radiotherapy | 18 Years - | EMD Serono | |
| Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene | NCT01124240 | Newly Diagnosed... | Cilengitide | 18 Years - | Northern Sydney and Central Coast Area Health Service | |
| Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene | NCT01124240 | Newly Diagnosed... | Cilengitide | 18 Years - | Northern Sydney and Central Coast Area Health Service | |
| Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer | NCT00884598 | Brain and Centr... Lung Cancer | cilengitide pharmacological... radiation thera... | 18 Years - | Universitätsmedizin Mannheim | |
| Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents | NCT01517776 | Gliomas | Cilengitide Temozolomide | 3 Years - 17 Years | Martin-Luther-Universität Halle-Wittenberg | |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status | NCT00813943 | Glioblastoma | Cilengitide (2-... cilengitide (5-... Temozolomide Radiotherapy | 18 Years - | EMD Serono | |
| Cilengitide in Treating Patients With Acute Myeloid Leukemia | NCT00089388 | Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... | cilengitide | 50 Years - | National Cancer Institute (NCI) | |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00085254 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | cilengitide temozolomide radiation thera... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00085254 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | cilengitide temozolomide radiation thera... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| EMD 121974 in Treating Patients With Advanced Solid Tumors | NCT00022113 | Unspecified Adu... | cilengitide pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide in Treating Patients With Prostate Cancer | NCT00121238 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide in Treating Patients With Prostate Cancer | NCT00121238 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | NCT00082875 | Stage III Melan... Stage IV Melano... | cilengitide pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | NCT00979862 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | Cediranib Malea... Cilengitide Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide in Treating Patients With Metastatic Prostate Cancer | NCT00103337 | Recurrent Prost... Stage IV Prosta... | cilengitide laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma | NCT00006222 | Sarcoma | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma | NCT00006222 | Sarcoma | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) | NCT00842712 | Carcinoma, Non-... | Cilengitide Cilengitide Cetuximab Cisplatin Cisplatin Gemcitabine Vinorelbine Cilengitide Cilengitide Cetuximab Chemotherapy | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Cilengitide in Treating Children With Refractory Primary Brain Tumors | NCT00063973 | Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | cilengitide laboratory biom... | - 21 Years | National Cancer Institute (NCI) | |
| Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene | NCT01124240 | Newly Diagnosed... | Cilengitide | 18 Years - | Northern Sydney and Central Coast Area Health Service | |
| Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | NCT00679354 | Childhood High-... Childhood High-... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | cilengitide laboratory biom... pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| Cilengitide Imaging Trial in Glioblastoma | NCT01558687 | Supratentorial ... | Drug (including... Standard therap... | 18 Years - 70 Years | Merck KGaA, Darmstadt, Germany | |
| Cilengitide in Treating Patients With Prostate Cancer | NCT00121238 | Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | cilengitide | 18 Years - | National Cancer Institute (NCI) | |
| Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | NCT00112866 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | cilengitide therapeutic con... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | NCT01782976 | Glioblastoma | Cilengitide Bevacizumab Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | NCT00679354 | Childhood High-... Childhood High-... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | cilengitide laboratory biom... pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme | NCT01122888 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Solid Neo... Recurrent Adult... | Cilengitide Clinical Observ... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | NCT00979862 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | Cediranib Malea... Cilengitide Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
